Hyperpolarized MR Imaging with Carbon-13 Pyruvate in the Human Body

Last updated: December 3, 2024
Sponsor: National Heart Centre Singapore
Overall Status: Active - Recruiting

Phase

2

Condition

High Cholesterol (Hyperlipidemia)

Diabetes Prevention

Chest Pain

Treatment

Hyperpolarized 13C-pyruvate

Clinical Study ID

NCT06645691
POLARIC-13
  • Ages 21-99
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

Positron emission tomography with 18F fluorodeoxyglucose (FDG) is the conventional imaging technique to provide information regarding tissue glucose uptake and has been highly clinically successful. However, it cannot assess downstream metabolism, which may be useful in the diagnosis and assessment of treatment response in a variety of diseases. Patients will also be exposed to ionizing radiation, the amount of exposure can vary depending on the dose of tracer administered, frequency of scans and duration of each scan. Carbon-13 (13C) magnetic resonance imaging (MRI) is particularly attractive for metabolic imaging because carbon serves as the backbone of nearly all organic molecules in the body. With this technique, the polarization increases to approximately 30%-40%, an increase of over 10,000 to 100,000-fold, thereby dramatically increasing the MRI signal . Whilst the role of 13C imaging has been demonstrated in many sites around the world, we aim to demonstrate the feasibility and application of 13C hyperpolarized imaging in healthy Singapore residents and patients with cardiovascular and/or cardiometabolic diseases.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Healthy Volunteers:

  1. Age 21 years and above

  2. No significant medical co-morbidities (such as chronic kidney disease, diabetesmellitus, heart failure, ischemic heart disease, previous strokes)

  3. No history of cancer

  4. Able and willing to comply with study procedures and provide signed informed consent

Patients with cardiovascular/cardiometabolic diseases:

  1. Age 21 years and above

  2. Physician diagnosed cardiovascular conditions: ischemic heart disease, inheritedcardiomyopathies (hypertrophic, dilated or infiltrative cardiomyopathies) and stableheart failure; and/or

  3. Cardiometabolic conditions (such as diabetes on medications, hypertension, centralobesity, fatty liver disease)

  4. Able and willing to comply with study procedures and provide signed informed consent

Exclusion

Exclusion Criteria:

  1. Standard contraindications for magnetic resonance procedures (such as implantablemedical devices, suspected presence of surgical apparatus or shrapnel, severeclaustrophobia)

  2. Unstable medical conditions (such as symptomatic heart failure, unstablehypertension/glucose levels as determined by investigators, symptomatic arrhythmias,angina)

  3. Pregnant or nursing women

  4. Known allergies to pyruvate or any of its components

Study Design

Total Participants: 200
Treatment Group(s): 1
Primary Treatment: Hyperpolarized 13C-pyruvate
Phase: 2
Study Start date:
October 17, 2024
Estimated Completion Date:
May 31, 2028

Study Description

Positron emission tomography with 18F fluorodeoxyglucose (FDG) is the conventional imaging technique to provide information regarding tissue glucose uptake and has been highly clinically successful. However, it cannot assess downstream metabolism, which may be useful in the diagnosis and assessment of treatment response in a variety of diseases. Patients will also be exposed to ionizing radiation, the amount of exposure can vary depending on the dose of tracer administered, frequency of scans and duration of each scan.

Carbon 13 (13C) magnetic resonance imaging (MRI) is particularly attractive for metabolic imaging because carbon serves as the backbone of nearly all organic molecules in the body. However, the low natural abundance of the 13C isotope at ~1.1% has made in vivo imaging extremely challenging. To improve the MR signal 13C nuclei, probes are synthetically enriched to increase the concentration of the 13C label in a molecule. MRI signal can be further increased by the process of hyperpolarization. At low temperature and high magnetic field, electrons have a very high level of polarization (ie, nearly all the electrons are aligned in the same direction). This high level of polarization can be transferred to 13C-labeled probes, increasing their MRI signals. This transfer of polarization is accomplished by mixing radicals (a source of free electrons) with the 13C-labeled probe(s) to be hyperpolarized and placing the mixture in a polarizer at a magnetic field typically of 3.0-5.0 T and at a low temperature (approximately 1 K). Microwave irradiation is then applied to transfer the polarization from unpaired electrons in a trityl radical to the 13C-labeled probe. The final solution retains a high level of polarization and can be formulated to be at physiologic pH, osmolarity, and temperature for in vivo injection and metabolic investigations.

With this technique, the polarization increases to approximately 30%-40%, an increase of over 10,000 to 100,000-fold, thereby dramatically increasing the MRI signal (Figure 1). The enhanced signal, however, is typically available only for a short period of time (1-2 minutes), as the polarization decays back to its thermal equilibrium level. Therefore, rapid imaging is needed to acquire high signal-to-noise ratio metabolic data with minimal polarization loss and to measure fast metabolic processes.

To date, hyperpolarized imaging technique has been performed in more than 800 healthy volunteers and patients; and in more than 1,200 studies in various clinical conditions.

HYPOTHESIS AND OBJECTIVES:

This proof-of-concept study to demonstrate feasibility and application of 13C hyperpolarized imaging in healthy Singapore residents and patients with cardiovascular/cardiometabolic diseases.

  1. To establish reference ranges in the metabolic products of hyperpolarized 13C-pyruvate (lactate, alanine and bicarbonate) in healthy volunteers and examine repeatability of the 13C hyperpolarized imaging sequences.

  2. To develop the application of 13C hyperpolarized imaging in patients with cardiovascular and cardiometabolic diseases.

Connect with a study center

  • National Heart Centre Singapore

    Singapore, 169609
    Singapore

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.